miRview™ squamous accurately differentiates NSCLC
Securing a clear diagnosis in patients with NSCLC is particularly important because treatment selection relies so heavily on it.
1-3 However, current NSCLC classification methodology cannot support the level of accuracy needed for informed decisions related to targeted lung cancer therapies.
4-6 Pathologists and physicians need a better way to diagnose patients and develop treatment plans in a timely fashion.
miRview™ squamous is a cutting-edge, microRNA-based molecular diagnostic tool that accurately classifies squamous and nonsquamous NSCLC. It offers
- High accuracy
- Simple interpretation
- Objectivity
- Standardization
- Quantitative analysis
- Cutting-edge molecular biology
- Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543-3551.
- Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22(11):2184-2191.
- Clark GM, Zborowski DM, Santabarbara P, et al, and the National Cancer Institute of Canada Clinical Trials Group study BR.21. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer. 2006;7(6):389-394.
- Stang A, Pohlabeln H, Müller KM, Jahn I, Giersiepen K, Jöckel KH. Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study. Lung Cancer. 2006;52(1):29-36.
- Field RW, Smith BJ, Platz CE, et al. Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review. J Natl Cancer Inst. 2004;96(14):1105-1107.
- Perelman M, Rosenwald S, Spector Y, et al. MicroRNA biomarkers for differential diagnosis of lung tumors. Presented at: United States and Canadian Academy of Pathology Annual Meeting; March 7-13, 2009; Boston, MA. Abstract 1630.
